Publications & Works

Articles 147
All (147)
SCI-E, SSCI, AHCI (122)
SCI-E, SSCI, AHCI, ESCI (134)
ESCI (12)
Scopus (131)
TRDizin (15)
Other Publications (5)
Papers Presented at Peer-Reviewed Scientific Conferences 76

1. Serum miR-181-5p, miR-214-3p, and miR-223-3p expression in epithelial ovarian cancer.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 29 May - 02 June 2026, vol.44, (Summary Text)

3. Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023, (Summary Text) Sustainable Development

18. Platin ile hızlı desensitizasyonun sitokin düzeylerine etkisi P -29

XXV. Ulusal Alerji ve Klinik İmmünoloji Kongresi, Antalya, Turkey, 17 - 21 November 2018, pp.111, (Full Text)

24. miRNAs leading to increase susceptibility of hereditary ovarian cancer

4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics, Dubai, United Arab Emirates, 19 - 20 April 2018, vol.12, pp.85, (Summary Text) Creative Commons License Sustainable Development

25. Frequency of rearrangements versus small indels mutations in BRCA1 and BRCA2 genes in Turkishspace patients with high risk breast and ovarian cancer

Joint Meeting on 4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics, Dubai, United Arab Emirates, 19 - 20 April 2018, vol.12, pp.86, (Full Text) Sustainable Development

26. The high expression levels of miRNAs in BRCA1 related hereditary ovarian cancer

Joint Meeting on 4th World Congress on Human Genetics & Genetic Diseases and 3rd International Conference on Molecular Medicine & Diagnostics, Dubai, United Arab Emirates, 19 - 20 April 2018, vol.12, pp.84, (Full Text) Sustainable Development

27. FREQUENCY OF BRCA1 AND BRCA2 MUTATIONS IN PATIENTS WITH UNSELECTED TRIPLE-NEGATIVE BREAST CANCER

VI. International Congress of Molecular Medicine, İstanbul, Turkey, 22 May - 25 September 2017, pp.282, (Full Text) Sustainable Development

30. Over Kanserinde HMGB1 ve IRE1'in Önemi

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, pp.159, (Full Text) Sustainable Development

31. Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a middle-income country, Turkey: Results of a Prospective Multicenter Study

15th St. Gallen International Breast Cancer Conference Primary Therapy of Early Breast Cancer, vİYANA, Austria, 15 - 18 March 2017, (Full Text) Sustainable Development

37. Panel Gene Testing For High Risk Early Age Breast Cancer Patients in Turkey

The 43rd ISOBM Annual Congress, Chicago, United States Of America, 1 - 06 September 2016, no.211, pp.55, (Full Text) Sustainable Development

38. Novel miRNAs in HIV Negative Kaposi’s Sarcoma Patients

The 43rd ISOBM Annual Congress, Chicago, United States Of America, 1 - 06 September 2016, no.210, pp.54, (Full Text) Sustainable Development

39. WHOLE GENOME EXPRESSION LEVELS OF miRNA IN HIV NEGATIVE KAPOSI'S SARCOMA

The 43rd ISOBM Annual Congress, Chicago, United States Of America, 1 - 06 September 2016, no.212, pp.56, (Full Text) Sustainable Development

43. ERKEN YAŞ MEME KANSER HASTALARINDA ÇOKLU GEN ANALİZİ

6.Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 23 - 27 March 2016, no.31, pp.238, (Full Text) Sustainable Development

46. Clinical and pathologic characteristics of ovarian cancer patients with BRCA1 and BRCA2 mutations in Turkish population

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32, (Summary Text) Sustainable Development

59. Nine versus52 weeks of adjuvant trastuzumab in early breast cancer:An observational study of the Turkısh Oncology Group

JOURNAL OF CLINICAL ONCOLOGY, Alexandrıa, United States Of America, 20 May 2011, vol.29, no.15, pp.629, (Summary Text) Sustainable Development

60. The ımpact of 21 gene recurrence score (RS)scores on treatment decisions:Retrospective evaluation in Turkish early-stage breast cancer(BC)patients

JOURNAL OF CLINICAL ONCOLOGY, Alexandrıa, United States Of America, 20 May 2011, vol.29, no.5, (Summary Text) Sustainable Development

62. Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer

JOURNAL OF CLINICAL ONCOLOGY, Alexandrıa, United States Of America, 20 May 2011, vol.29, no.15, (Summary Text) Sustainable Development

63. Association between glutathione s-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients

JOURNAL OF CLINICAL ONCOLOGY, Alexandrıa, United States Of America, 20 May 2010, vol.28, no.15, (Summary Text) Sustainable Development

64. Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain

JOURNAL OF CLINICAL ONCOLOGY, Alexandrıa, United States Of America, 20 May 2010, vol.28, no.15, (Summary Text) Sustainable Development

65. The future of breast cancer research and practice in Asia, Latin America, and the Middle East/North Africa: a qualitative horizon scanning analysis.

31st Annual San Antonio Breast Cancer Symposium, Phıladelphıa, United States Of America, 15 January 2009, vol.69, no.2, pp.328-329, (Summary Text) Sustainable Development

69. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.229, (Summary Text)

70. Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.174, (Summary Text)

71. Detection of circulating breast cancer cells in relation to therapy.

41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23, (Summary Text)

72. Clinical features and prognosis of Turkish epithelial ovarian cancer patients with BRCA1 and BRCA2 mutations.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text) Sustainable Development

73. Immunoreactivity to SOX-1,-2,-3 and ZIC2 antigens and correlation to survival in small cell lung cancer (SCLC).

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text)

74. Oral etoposide in patients with small cell lung cancer

EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1072, (Summary Text) Sustainable Development

75. Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)

EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1178, (Summary Text)
Books 2
Metrics

Publication

225

Publication (WoS)

146

Publication (Scopus)

131

Citation (WoS)

1221

H-Index (WoS)

19

Citation (Scopus)

1379

H-Index (Scopus)

22

Citation (Scholar)

335

H-Index (Scholar)

10

Project

15

Thesis Advisory

1

Open Access

16
UN Sustainable Development Goals